Liva Healthcare secures €24.5m funding - led by Verlinvest - to drive European leadership in digital chronic disease prevention and management
Liva Healthcare (“Liva”), a European market leader in scalable digital health coaching, has secured a new funding round of EUR 24.5 million, led by Verlinvest, the go-to investor for mission-driven entrepreneurs and category-defining global consumer brands. The investment will enable Liva to strengthen its position as a European leader in digital health and lifestyle coaching for chronic disease prevention and management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005831/en/
Liva Healthcare secures €24.5m funding - led by Verlinvest - to drive European leadership in digital chronic disease prevention and management (Photo: Business Wire)
Liva is a health tech company headquartered in Copenhagen and London with the mission to improve the lives of people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving positive behavioural change. Liva blends scalable health coaching focused on personal human relationships with an intuitive and user-friendly interface. Liva was founded in 2015 by the team behind independent health information portal NetDoctor.com.
The on-going Covid-19 pandemic has led to a significant shift in acceptance of remote healthcare by European consumers. This shift in acceptance and the subsequent patient behaviour has given Liva a significant increase in interest from public healthcare providers and life science companies in 2020.
Liva is used by clients such as Novo Nordisk, AXA Health, Amgen, City of Copenhagen, Bupa Australia and several other key players in public healthcare, insurance and life science industries globally. Liva is also a partner to NHS England on its world-leading National Diabetes Prevention Programme. Liva is currently operational in Britain, Australia, Ireland, Holland, Belgium, Denmark, Sweden, and Finland with operations currently being setup in Germany and Switzerland.
“This new funding, from one of Europe’s strongest purpose-led, consumer growth investors, will substantially accelerate our expansion in core European markets,” says André Sode, CEO of Liva Healthcare. “COVID-19 has demonstrated how effective remote digital health solutions can be. With healthcare providers around the world looking for scalable solutions to combat the rise in diabetes and obesity, we are ideally placed to support and have experienced a significant increase in interest as a result.”
“This investment represents a major new entry into digital health for Verlinvest, where technology is fuelling consumer revolutions,” says Simone Sallustio, Executive Director at Verlinvest. “Digital healthcare has been vital in getting treatment to patients during the pandemic and this trend will continue as effective virtual programmes give people more flexible healthcare options. Liva’s advanced technology and proven clinical outcomes set it apart from its competitors. In this exciting and rapidly evolving space, Liva’s experience and established partnerships represent a strategic choice for Verlinvest.”
About Liva Healthcare:
Liva Healthcare is a leading provider of scalable digital health coaching, delivering human-centric coaching through an advanced app to help people prevent and manage obesity, prediabetes, type 2 diabetes and cardiovascular diseases.
For more information: livahealthcare.com, LinkedIn and Twitter.
About Verlinvest:
Verlinvest is a privately-owned family investment company based in Brussels with offices in New York, London, and Singapore.
For more information: www.verlinvest.com and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005831/en/
Contact information
Lewis Oakley
+44-7767-887-035
lewis@milkandhoneypr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom